Healthcare · Biotechnology · NASDAQ

Immunitybio Inc (IBRX) Stock Price, Analysis & Trade Signals

$6.02-0.55 (-8.37%)

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell)…

IBRX key stats

Market Cap
$6.4B
P/E Ratio
0
Forward P/E
60.24
EPS
-1.06
52 Week Range
$0.00 – $12.43
50-Day Avg
8.42
200-Day Avg
7.98
Revenue (TTM)
$182.57M
Revenue Growth (Qtr YoY)
52.3%
Profit Margin
0%
Operating Margin (TTM)
-150.2%
Beta
0.17
Volume
10.64M
30-Day Avg Volume
12.93M
Next Earnings
Feb 22, 2027
Estimated EPS
-0.14
CEO
Richard Gerald Adcock
Employees
688
IPO Date
Jul 28, 2015

IBRX on X: what traders are saying

  • Antonio Linares @alc2022 · Nov 13, 2026

    I'm disappointed to see $IBRX not hold a Q3 earnings call. Communication with shareholders is important.

  • Antonio Linares @alc2022 · Nov 13, 2026

    It's not widely understood that my portfolio is a small collection of massively asymmetric bets If just one works out like I expect it to, like $AMD, the portfolio obliterates the index It's very early days for the ALC portfolio, with $HIMS, $DUOL, $IBRX and $NAUT at infancy…

  • Antonio Linares @alc2022 · Nov 4, 2026

    Companies with no actual competition: 1. $PLTR 2. $DUOL 3. $HIMS 4. $TSLA 5. $SPOT 6. $NAUT 7. $IBRX

  • Antonio Linares @alc2022 · Oct 27, 2026

    Learn the mental framework behind my $AMD, $PLTR, $NAUT and $IBRX picks https://t.co/XnYjPjtXxK

  • Retail Mourinho @retail_mourinho · Oct 23, 2026

    THE FINX MARKET GUIDE FOR BEGINNERS A watchlist by sector and theme. Neoclouds & AI Compute $NBIS $IREN $CRWV Photonics & AI Connectivity $AAOI $CRDO $LITE $COHR $ALAB Space $ASTS $RKLB $SPCX $FLY $VOYG Biotech & Life Sciences $NAUT $ABCL $IBRX Robotics & Automation $OUST…

IBRX analyst rating & price target

4 analysts rate IBRX Buy on consensus.

1Strong Buy
3Buy
0Hold
0Sell
0Strong Sell

Consensus price target: $14.25 (+136.71% upside from $6.02)

Recent IBRX insider transactions

InsiderDateTransactionSharesValue
Simon Barry J.
director
Oct 5, 2026Sale25,000$268.76K
Selecky Christobel
director
Jun 30, 2026Sale1,000$9K
Selecky Christobel
director
Jun 29, 2026Sale95,722$862.22K
Simon Barry J.
director
Jun 24, 2026Sale25,000$196.91K
Simon Barry J.
director
Jun 4, 2026Sale23,033$165.31K

Immunitybio Inc annual revenue & net income

Fiscal yearRevenueRevenue YoYNet income
2025$113.29M+668.31%$-351.4M
2024$14.75M+2270.58%$-413.56M
2023$622K+159.17%$-583.2M

Stock data for IBRX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics